These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933 [TBL] [Abstract][Full Text] [Related]
7. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167 [TBL] [Abstract][Full Text] [Related]
9. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768 [TBL] [Abstract][Full Text] [Related]
10. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT]. Haug AR; Assmann G; Rist C; Tiling R; Schmidt GP; Bartenstein P; Hacker M Radiologe; 2010 Apr; 50(4):349-54. PubMed ID: 20333502 [TBL] [Abstract][Full Text] [Related]
11. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438 [TBL] [Abstract][Full Text] [Related]
12. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
15. Head-to-Head Comparison of Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731 [No Abstract] [Full Text] [Related]
16. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. Fendler WP; Barrio M; Spick C; Allen-Auerbach M; Ambrosini V; Benz M; Bluemel C; Grewal RK; Lapa C; Miederer M; Nicolas G; Schuster T; Czernin J; Herrmann K J Nucl Med; 2017 Feb; 58(2):307-311. PubMed ID: 27539839 [TBL] [Abstract][Full Text] [Related]
17. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695 [TBL] [Abstract][Full Text] [Related]